News Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
0.6698 ^USD	+3.00%		-8.01%	-3.21%

May. 14	Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target	MT
May. 09	Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sensei Biotherapeutics : Bio SNS-101 Data Webcast	Jun. 03	PU
Sensei Biotherapeutics : Company Presentation June 2024	Jun. 01	PU
ASCO 2024: Topline SNS-101 Dose Escalation Data	Jun. 01	PU
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference	May. 30	AQ
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101	May. 23	AQ
Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target	May. 14	MT
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	AQ
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	Apr. 24	AQ
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	Apr. 24	CI
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference	Apr. 09	AQ
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment	Apr. 04	AQ
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	Apr. 04	CI
Sensei Biotherapeutics : Company Presentation April 2024	Apr. 02	PU
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	Apr. 02	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium	Mar. 22	AQ
Keystone Symposia 2024: Preclinical data for SNS-101	Mar. 21	PU
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences	Mar. 06	AQ
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	Feb. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 06:59 am EST